Biomedical Engineering Reference
In-Depth Information
FURTHER READINGS
Hancock, A.A. 2006. The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology
of histamine H
3
antagonists/inverse agonists.
Biochem. Pharmacol
. 71:1103-1113.
Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R.,
and Haas, H.L. 1997. International Union of Pharmacology. XIII. Classii cation of histamine receptors.
Pharmacol. Rev
. 49:253-278.
Leurs, R., Bakker, R.A., Timmerman, H., and de Esch, I.J. 2005. The histamine H
3
receptor: From gene cloning
to H
3
receptor drugs.
Nat. Rev. Drug Discovery
4:107-120.
Thurmond, R.L., Gelfand, E.W., and Dunford, P.J. 2008. The role of histamine H
1
and H
4
receptors in allergic
inl ammation: The search for new antihistamines.
Nat. Rev. Drug Discovery
7:41-53.
Zhang, M.Q., Leurs, R., and Timmerman, H. 1997. Histamine H
1
-receptor antagonists. In M.E. Wolff (ed.),
Burger's Medicinal Chemistry and Drug Discovery
, 5th edn. New York: John Wiley & Sons, Inc., p. 495.